



DSECT/DSEN Monthly Seminar Series

“Drug Hypersensitivity: Mechanistic and clinical implications for prediction and diagnosis”

Presented by

Baset A Elzagallaai, BSc Pharm, MSc, PhD

Postdoctoral Associate, Department of Paediatrics, Schulich School of Medicine and Dentistry and Robarts Research Institute, Western University

Thursday, Feb 23, 2017 at 3:00-4:00pm EDT

Online webinar (GoToWebinar*)

RSVP: <https://attendeegotowebinar.com/register/6387157984359768578>

Drug hypersensitivity reactions (DHRs) are adverse drug reactions (ADRs) that belong to type B ADRs (idiosyncratic reactions). While individually uncommon, collectively they are among the most serious ADRs seen clinically. Prediction and diagnosis of DHRs are difficult because of their varied clinical presentation and lack of understanding of the underlying pathophysiology. However, a body of evidence exists that support the involvement of the immune system in the majority of DHRs. This webinar will give an overview of the current understanding of the pathophysiology of DHRs and methods used for prediction and diagnosis.

Resources:

Elzagallaai AA, Rieder MJ. In vitro testing for diagnosis of idiosyncratic adverse drug reactions: Implications for pathophysiology. *Br J Clin Pharmacol.* 2015 Oct;80(4):889-900.

Uetrecht J, Naisbitt DJ. Idiosyncratic adverse drug reactions: current concepts. *Pharmacol Rev.* 2013 Mar 8;65(2):779-808.

The ***Drug Safety and Effectiveness Cross-Disciplinary Training (DSECT) program*** and the ***Drug Safety and Effectiveness Network (DSEN)*** are presenting a monthly online seminar series for faculty, staff, trainees, decision-makers, and other stakeholders engaged in the field of drug safety and effectiveness.

For more information, please visit www.safeandeffectiverx.com or contact:

Lisa Dolovich
DSECT Principal Investigator
Email: ldolovic@mcmaster.ca

Melissa Pirrie
DSECT Program Coordinator
Phone: (905) 525-9140 x27766
E-mail: pirrie@mcmaster.ca